查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1729602

日本核子造影市場報告（按產品（設備、放射性同位素）、應用（SPECT 應用、PET 應用）和地區分類，2025 年至 2033 年）

Japan Nuclear Imaging Market Report by Product (Equipment, Radioisotope), Application (SPECT Applications, PET Applications), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2024 年，日本核子造影市場規模達到 6.03 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 10.4 億美元，2025-2033 年期間的成長率 (CAGR) 為 6.2%。該市場正在經歷顯著成長，主要原因是技術進步、老年人口成長和慢性病發病率上升。政府推動早期診斷的舉措、混合成像技術的採用、以及對研發 (R&D) 的大量投資以提高診斷的精度和效率，正在推動市場成長。

日本核子造影市場分析：

  • 主要市場促進因素：關鍵市場促進因素包括癌症和心血管疾病等慢性病盛行率的上升，這需要先進的診斷影像技術。同時，老年人口的成長進一步刺激了對先進影像技術的需求，因為與成年人相比，老年人更容易出現此類疾病。在大量研發投入的支援下，影像設備的技術進步進一步提高了診斷程序的準確性和效率。此外，政府促進早期疾病檢測和改善醫療保健基礎設施的措施和政策極大地促進了日本核子造影市場的成長。核子醫學與其他影像方式結合的混合影像技術的日益普及也為市場帶來了積極的前景。
  • 主要市場趨勢：主要市場趨勢包括 PET/CT 和 SPECT/CT 等混合影像技術的日益普及，這些技術透過結合功能和解剖成像來提高診斷準確性。人們也開始明顯轉向使用先進的放射性藥物，因為這些藥物可以提供更好的成像品質和特定的診斷。市場正在經歷人工智慧和機器學習融合的顯著成長，以改善影像分析並簡化工作流程。此外，對個人化醫療的關注正在推動客製化核成像解決方案的發展，進而推動日本核子成像市場的成長。如今，隨著人們努力減少輻射暴露和提高成像系統的效率，環境永續性正成為優先事項。
  • 競爭格局：市場的主要參與者正在大力投資研發（R&D）以推出創新的影像技術。如今，公司也在建立策略合作夥伴關係，以擴大其產品組合和市場範圍。此外，他們還強調環境永續性，透過創造更有效率、低輻射成像解決方案來滿足監管標準和醫療保健需求。
  • 挑戰與機會：市場面臨各種挑戰，例如與先進成像技術和放射性藥物相關的高成本，這可能會限制其可及性和可負擔性。新的影像劑和設備的監管障礙和嚴格的核准流程也造成了重大障礙。然而，這些挑戰也創造了重大機會。慢性病發病率的上升和老年人口的增加推動了對精確診斷工具的需求。人工智慧和機器學習等技術進步為提高成像精度和效率提供了前景。此外，政府推動早期診斷和個人化醫療的措施也為市場提供了重要的成長途徑。產業參與者和醫療機構之間的合作進一步促進了日本核子造影市場的成長和創新。

日本核子造影市場趨勢：

慢性病盛行率上升

日本癌症發生率不斷上升，需要先進的診斷工具，這使得核子影像對於早期發現、準確分期和監測治療反應至關重要。根據日本國立醫學圖書館發布的報告，自1981年以來，癌症一直是日本最大的死亡原因，佔總死亡人數的三分之一。 2022 年新增癌症病例 1,019,000 例，癌症死亡人數 380,400 人。 PET/CT 等技術可提供癌症組織的詳細影像，有助於制定個人化治療方案並改善患者預後。同樣，心血管疾病這一主要的健康問題也從 SPECT 和 PET 掃描等核子造影方式中受益匪淺。這些技術有助於評估心肌灌注、檢測缺血和評估心臟功能，從而促進及時和精確的干涉。對核子造影的日益依賴增強了對這些慢性疾病的管理，有助於改善健康結果並延長患者的生存期。

老年人口不斷增加

日本人口老化大大增加了對核子影像服務的需求，因為老年人通常需要頻繁進行診斷程序來治療與年齡相關的健康問題。根據BBC報道，全國資料顯示，日本1.25億人口中，29.1%的人年齡在65歲以上。在日本，預計到2040年，65歲以上的人口將佔總人口的34.8％。癌症、心血管疾病和神經系統疾病等疾病在老年人中更為普遍，因此需要先進的影像技術來進行早期發現和準確診斷。此外，與年齡相關的退化性疾病（如阿茲海默症）也可透過核子影像進行早期介入。老年人口的成長推動了日本核子造影市場的成長，確保老年人獲得更好的醫療保健結果和生活品質。

政府投資增加

日本政府對醫療保健基礎設施的投資對於促進核子造影市場的發展至關重要。這些投資包括為最先進的影像技術和設施提供資金，確保醫療保健提供者能夠使用最新的診斷工具。例如，日本健康2025計畫旨在改變全球醫療保健，並專注於醫療創新和技術。該國的醫療保健產業正在不斷發展，包括矽谷日本創新園區等舉措以及精準醫療和再生醫學的進步。日本健康致力於將日本與世界聯繫起來，並將其醫療保健產業提升到全球標準。這些進步提高了診斷的準確性和患者護理，推動了核成像的普及。此外，有利的監管政策透過簡化新成像技術和放射性藥物的核准流程來支持市場的成長。政府推動核子造影研究和開發的措施促進了創新並推動了尖端技術和治療方法的引進，最終改善了整體醫療保健系統和患者的治療效果。

日本核子造影市場細分：

按產品分類：

  • 裝置
  • 放射性同位素
    • SPECT放射性同位素
      • 锝-99m（TC-99m）
      • 鉈-201（TI-201）
      • 鎵（Ga-67）
      • 碘（I-123）
      • 其他
    • PET放射性同位素
      • 氟-18（F-18）
      • 銣-82（RB-82）
      • 其他

日本核子成像設備市場是該國先進醫療保健基礎設施的重要組成部分。關鍵設備包括單光子發射電腦斷層掃描 (SPECT) 和正子斷層掃描 (PET) 掃描儀，它們對於診斷癌症、心血管疾病和神經系統疾病等各種疾病至關重要。日本人口老化、慢性病盛行率上升以及影像技術的進步推動了此類設備的需求。此外，成像設備中人工智慧和機器學習的整合提高了診斷的準確性和效率，進一步推動了市場成長。對醫療保健基礎設施的持續投資和對早期疾病檢測意識的提高，極大地促進了日本核成像設備市場的擴張。

放射性同位素是日本核子造影市場的基礎，為 SPECT 和 PET 影像技術提供必要的追蹤劑。 SPECT 放射性同位素，例如锝-99m (Tc-99m) 和鉈-201 (Tl-201)，因其良好的特性和可用性而被廣泛用於心臟、骨骼和腫瘤成像。 PET 放射性同位素，包括氟-18 (F-18) 和銣-82 (Rb-82)，可提供對檢測癌症、神經系統疾病和心血管疾病至關重要的高解析度影像。這些疾病的日益普及推動了對 SPECT 和 PET 放射性同位素的需求。日本強大的醫療保健基礎設施，加上其對先進核醫學研究的重視，支持了這些放射性同位素的廣泛應用，確保了精確的診斷和有效的疾病管理。

按應用分類：

  • SPECT 應用
    • 骨科
    • 甲狀腺
    • 心臟病學
    • 其他
  • PET應用
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 其他

在日本，SPECT 應用對於診斷和監測各種健康狀況至關重要。骨科可以利用 SPECT 影像來檢測骨骼異常和骨折。甲狀腺影像利用 SPECT 來評估甲狀腺功能並檢測甲狀腺功能亢進或甲狀腺癌等疾病。心臟科應用使用 SPECT 來評估心肌灌注和診斷冠狀動脈疾病。其他應用包括癲癇和失智症的腦部影像。這些疾病的盛行率不斷上升，加上 SPECT 技術的進步，推動了日本醫療保健領域對 SPECT 應用的需求，確保了精確的診斷和改善患者的治療效果。

PET 應用是日本核子造影市場不可或缺的一部分，為各個醫療領域提供高解析度影像。腫瘤學嚴重依賴 PET 來檢測和分期癌症、監測治療反應和復發。心臟病學應用使用 PET 來評估心肌灌注和活力，有助於診斷和治療心臟病。神經病學受益於 PET 影像來診斷和評估阿茲海默症和癲癇等神經系統疾病。其他應用包括感染和發炎成像。日本癌症、心血管疾病和神經系統疾病發病率的不斷上升，推動了對 PET 應用的需求，以增強早期發現和有效的治療策略。

日本核子造影市場最新發展：

  • 2024 年 4 月，博萊科集團成立博萊科日本公司，取代合資公司博萊科衛材，在日本建立直接業務。這項搬遷活動在義大利駐東京大使館舉行，恰逢義大利製造全國週。該公司旨在滿足日本市場對先進醫療產品和成像技術日益成長的需求。 Bracco Japan 將專注於開發新產品並加強與當地醫療界的關係。
  • 2024 年 4 月，GE 醫療集團在孟加拉為其 A1-Sure 超音波系統啟動了一個新的翻新部門，旨在改善醫療服務不足的二線和三線城市的醫療服務。該計劃包括高品質的翻新超音波設備，並提供完整的檢查、保固和融資選擇。此舉旨在為大城市以外地區提供可負擔的醫療保健解決方案，為當地就業和能力建設創造機會。

本報告回答的關鍵問題：

  • 日本核子成像市場迄今表現如何？未來幾年將如何表現？
  • 日本核子造影市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對日本核子造影市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表了日本最具吸引力的核子成像市場？
  • 根據產品，市場是如何分類的？
  • 日本核子造影市場最有吸引力的產品是什麼？
  • 根據應用，市場詳細情形如何？
  • 日本核子造影市場最有吸引力的應用是什麼？
  • 根據地區，市場是如何分類的？
  • 日本核子造影市場中最具吸引力的地區是哪一個？
  • 市場的競爭結構是怎麼樣的？
  • 日本核子造影市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 日本核子成像市場迄今表現如何？未來幾年將如何表現？
  • 日本核子造影市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對日本核子造影市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表了日本最具吸引力的核子成像市場？
  • 根據產品，市場是如何分類的？
  • 日本核子造影市場最有吸引力的產品是什麼？
  • 根據應用，市場詳細情形如何？
  • 日本核子造影市場最有吸引力的應用是什麼？
  • 根據地區，市場是如何分類的？
  • 日本核子造影市場中最具吸引力的地區是哪一個？
  • 市場的競爭結構是怎麼樣的？
  • 日本核子造影市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：日本核子造影市場－簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭情報

第5章：日本核子造影市場格局

  • 歷史與當前市場趨勢（2019-2024）
  • 市場預測（2025-2033）

第6章：日本核子造影市場-細分：依產品

  • 裝置
    • 概述
  • 放射性同位素
    • 概述
    • 市場區隔
      • SPECT放射性同位素
        • 锝-99m（TC-99m）
        • 鉈-201（TI-201）
        • 鎵（Ga-67）
        • 碘（I-123）
        • 其他
      • PET放射性同位素
        • 氟-18（F-18）
        • 銣-82（RB-82）
        • 其他

第7章：日本核子造影市場-細分：依應用

  • SPECT 應用
    • 概述
    • 市場區隔
      • 骨科
      • 甲狀腺
      • 心臟病學
      • 其他
  • PET應用
    • 概述
    • 市場區隔
      • 腫瘤學
      • 心臟病學
      • 神經病學
      • 其他

第 8 章：日本核子造影市場-競爭格局

  • 概述
  • 市場結構
  • 市場參與者定位
  • 最佳獲勝策略
  • 競爭儀錶板
  • 公司評估象限

第9章：關鍵參與者簡介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 10 章：日本核子造影市場-產業分析

  • 促進因素、限制因素和機遇
    • 概述
    • 驅動程式
    • 限制
    • 機會
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價值鏈分析

第 11 章：附錄

簡介目錄
Product Code: SR112025A16049

Japan nuclear imaging market size reached USD 603 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,040 Million by 2033, exhibiting a growth rate (CAGR) of 6.2% during 2025-2033. The market is experiencing significant growth mainly driven by technological advancements, growing geriatric population and increase in incidence of chronic disease. Government initiatives promoting early diagnosis, adoption of hybrid imaging technologies, significant investment in research and development (R&D) to enhance diagnostic precision and efficiency is driving the market growth.

Japan Nuclear Imaging Market Analysis:

  • Major Market Drivers: Key market drivers include the rising in prevalence of chronic disease, such as cancer and cardiovascular diseases, which necessitates advanced diagnostic imaging technologies. In line with this, the growing geriatric population further fuels the demand for advanced imaging technologies as older population are more prone to such conditions as compared to adults. Technological advancements in imaging equipment supported by substantial investment in research and development (R&D) further enhances the accuracy and efficiency of diagnostic procedures. Furthermore, the government initiatives and policies promoting early disease detection and improving healthcare infrastructure significantly boosts the Japan nuclear imaging market growth. The rising adoption of hybrid imaging techniques combining nuclear medicine with other imaging modalities also create a positive outlook for the market.
  • Key Market Trends: Key market trends include the growing adoption of hybrid imaging technologies such as PET/CT and SPECT/CT which offers enhanced diagnostic accuracy by combining functional and anatomical imaging. There is also significant shift towards the use of advanced radiopharmaceuticals which provide better imaging qualities and target specific diagnostics. The market is experiencing a significant rise in integration of artificial intelligence and machine learning to improve image analysis and streamline workflows. Furthermore, the focus on personalized medicine is driving the development of tailored nuclear imaging solutions which in turn is driving the Japan nuclear imaging market growth. Environmental sustainability is becoming a priority nowadays with efforts to reduce radiation exposure and improve efficiency of imaging systems.
  • Competitive Landscape: Key players in the market are heavily investing in research and development (R&D) to introduce innovative imaging technologies. Companies nowadays are also engaging in strategic partnerships and collaborations to expand their product portfolios and market reach. Furthermore, they are emphasizing environmental sustainability by creating more efficient, low radiation imaging solutions in order to meet regulatory standards and address healthcare needs.
  • Challenges and Opportunities: The market faces various challenges such as high costs associated with advanced imaging technologies and radiopharmaceuticals which can limit the accessibility and affordability. Regulatory hurdles and strict approval processes for new imaging agents and equipment also create significant barriers. However, these challenges create significant opportunities as well. The rising incidence of chronic disease and the growing geriatric population is driving the demand for precise diagnostic tools. Technological advancements including artificial intelligence and machine learning offers prospects for improved imaging accuracy and efficiency. Furthermore, government initiatives promoting early diagnosis and personalized medicine also present significant market growth avenues. Collaborations between industry players and in healthcare institutions are further enhancing the Japan nuclear imaging market growth and innovation.

Japan Nuclear Imaging Market Trends:

Rising Prevalence of Chronic Diseases

Rising prevalence of cancer in Japan necessitates advanced diagnostic tool which makes nuclear imaging important for early detection, accurate staging and monitoring treatment responses. According to a report published by National Library of Medicine, cancer has been the leading cause of death in Japan since 1981 accounting for 1/3 of total deaths. There were 1,019,000 new cancer cases and 380,400 cancer deaths in 2022. Techniques like PET/CT provide detailed images of cancerous tissues aiding in personalized treatment plans and improving patient outcomes. Similarly, cardiovascular disease a major health concern benefits significantly from nuclear imaging modalities such as SPECT and PET scans. These techniques help in assessing myocardial perfusion, detecting ischemia, and evaluating cardiac function, thereby facilitating timely and precise interventions. The growing reliance on nuclear imaging enhances the management of these chronic diseases, contributing to better health outcomes and prolonged patient survival.

Rising Geriatric Population

Japan's aging population significantly increases the demand for nuclear imaging services as older adults often require frequent diagnostic procedures for age-related health issues. According to an article published by BBC, national data shows that 29.1% of 125 million population in Japan is aged 65 or older. In Japan, people aged over 65 are expected to account for 34.8% of population by 2040. Conditions such as cancer, cardiovascular diseases and neurological disorders are more prevalent in elderly people which necessitates advanced imaging technologies for early detection and accurate diagnosis. Furthermore, age-related degenerative conditions such as Alzheimer disease benefits from nuclear imaging for early intervention. The rising geriatric demographic drives the Japan nuclear imaging market growth, ensuring better healthcare outcomes and quality of life for older adults.

Increase in Government Investments

Government investments in healthcare infrastructure in Japan are crucial in bolstering the nuclear imaging market. These investments include funding for state-of-the-art imaging technologies and facilities, ensuring that healthcare providers have access to the latest diagnostic tools. For instance, Japan Health 2025 aims to transform global healthcare with a focus on medical innovation and technology. The country's healthcare sector is evolving, with initiatives like the Japan Innovation Campus in Silicon Valley and advancements in Precision Medicine and regenerative medicine. Japan Health aspires to connect Japan with the world and elevate its healthcare industry to global standards. Such advancements improve diagnostic accuracy and patient care, driving the adoption of nuclear imaging. Furthermore, favorable regulatory policies support the market's growth by streamlining the approval process for new imaging technologies and radiopharmaceuticals. Government initiatives promoting research and development in nuclear imaging foster innovation and facilitate the introduction of cutting-edge techniques and treatments, ultimately enhancing the overall healthcare system and patient outcomes.

Japan Nuclear Imaging Market Segmentation:

Breakup by Product:

  • Equipment
  • Radioisotope
    • SPECT Radioisotopes
      • Technetium-99m (TC-99m)
      • Thallium-201 (TI-201)
      • Gallium (Ga-67)
      • Iodine (I-123)
      • Others
    • PET Radioisotopes
      • Fluorine-18 (F-18)
      • Rubidium-82 (RB-82)
      • Others

The Japan nuclear imaging market for equipment is a vital component of the country's advanced healthcare infrastructure. Key equipment includes Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners, which are essential for diagnosing various conditions, including cancer, cardiovascular diseases, and neurological disorders. The demand for such equipment is driven by Japan's aging population, increasing prevalence of chronic diseases, and advancements in imaging technologies. Moreover, the integration of artificial intelligence and machine learning in imaging equipment enhances diagnostic accuracy and efficiency, further propelling market growth. Continuous investments in healthcare infrastructure and rising awareness about early disease detection contribute significantly to the expansion of the nuclear imaging equipment market in Japan.

Radioisotopes are fundamental to Japan's nuclear imaging market, providing the necessary tracers for both SPECT and PET imaging techniques. SPECT radioisotopes, such as Technetium-99m (Tc-99m) and Thallium-201 (Tl-201), are extensively used for cardiac, bone, and tumor imaging due to their favorable properties and availability. PET radioisotopes, including Fluorine-18 (F-18) and Rubidium-82 (Rb-82), offer high-resolution imaging crucial for detecting cancer, neurological disorders, and cardiovascular diseases. The increasing prevalence of these conditions drives the demand for both SPECT and PET radioisotopes. Japan's robust healthcare infrastructure, coupled with its focus on advanced nuclear medicine research, supports the growing utilization of these radioisotopes, ensuring precise diagnostics and effective disease management.

Breakup by Application:

  • SPECT Applications
    • Orthopedics
    • Thyroid
    • Cardiology
    • Others
  • PET Applications
    • Oncology
    • Cardiology
    • Neurology
    • Others

In Japan, SPECT applications are pivotal for diagnosing and monitoring various health conditions. Orthopedics benefits from SPECT imaging in detecting bone abnormalities and fractures. Thyroid imaging utilizes SPECT to assess thyroid function and detect disorders like hyperthyroidism or thyroid cancer. Cardiology applications use SPECT to evaluate myocardial perfusion and diagnose coronary artery disease. Other applications include brain imaging for epilepsy and dementia. The rising prevalence of these conditions, coupled with advancements in SPECT technology, drives the demand for SPECT applications in Japan's healthcare sector, ensuring precise diagnostics and improved patient outcomes.

PET applications are integral to Japan's nuclear imaging market, offering high-resolution imaging for various medical fields. Oncology heavily relies on PET for detecting and staging cancers, monitoring treatment response, and recurrence. Cardiology applications use PET to assess myocardial perfusion and viability, aiding in the diagnosis and management of heart diseases. Neurology benefits from PET imaging in diagnosing and evaluating neurological disorders like Alzheimer's disease and epilepsy. Other applications include infection and inflammation imaging. The increasing incidence of cancer, cardiovascular, and neurological diseases in Japan fuels the demand for PET applications, enhancing early detection and effective treatment strategies.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
  • The Japan Nuclear Imaging Market is highly competitive, characterized by the presence of various key players. These companies are leading the market through technological innovations, extensive research and development, and strategic collaborations. For instance, in April 2024, FUJIFILM Toyama Chemical and Synplogen entered a strategic business alliance on CDMO services for mRNA therapeutics. This alliance expands CDMO services to cover mRNA sequence design and plasmid DNA synthesis. Synplogen will provide mRNA sequence design and plasmid DNA synthesis services. By integrating expertise in mRNA sequence design and plasmid DNA synthesis, the companies aim to maximize customer value in the mRNA therapeutics industry and support its growth. Additionally, smaller domestic companies and startups are also contributing to market dynamism by introducing niche products and services. The market's competitiveness is further intensified by the increasing adoption of nuclear imaging for early diagnosis and treatment of chronic diseases.

Japan Nuclear Imaging Market Recent Developments:

  • In April 2024, Bracco Group establishes a direct presence in Japan with the launch of Bracco Japan, replacing the joint venture Bracco Eisai. The move is celebrated at the Italian Embassy in Tokyo and coincides with the National Made in Italy Week. The company aims to meet the growing demands for advanced medical products and imaging technologies in the Japanese market. Bracco Japan will focus on developing new products and strengthening relationships with the local medical community.
  • In April 2024, GE HealthCare launched a new refurbishing unit in Bangladesh for its A1-Sure Ultrasound Systems, aiming to improve healthcare access in underserved Tier 2 and Tier 3 cities. The initiative includes high-quality refurbished ultrasound equipment complete with inspections, warranty, and financing options. This move seeks to offer affordable healthcare solutions beyond major cities, creating opportunities for local employment and capacity building.

Key Questions Answered in This Report:

  • How has the Japan nuclear imaging market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the Japan nuclear imaging market?
  • What is the impact of each driver, restraint, and opportunity on the Japan nuclear imaging market?
  • What are the key regional markets?
  • Which countries represent the most attractive Japan nuclear imaging market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the Japan nuclear imaging market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the Japan nuclear imaging market?
  • What is the breakup of the market based on the region?
  • Which is the most attractive region in the Japan nuclear imaging market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the Japan nuclear imaging market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Nuclear Imaging Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Nuclear Imaging Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Nuclear Imaging Market - Breakup by Product

  • 6.1 Equipment
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Radioisotope
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 SPECT Radioisotopes
        • 6.2.3.1.1 Technetium-99m (TC-99m)
        • 6.2.3.1.2 Thallium-201 (TI-201)
        • 6.2.3.1.3 Gallium (Ga-67)
        • 6.2.3.1.4 Iodine (I-123)
        • 6.2.3.1.5 Others
      • 6.2.3.2 PET Radioisotopes
        • 6.2.3.2.1 Fluorine-18 (F-18)
        • 6.2.3.2.2 Rubidium-82 (RB-82)
        • 6.2.3.2.3 Others
    • 6.2.4 Market Forecast (2025-2033)

7 Japan Nuclear Imaging Market - Breakup by Application

  • 7.1 SPECT Applications
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Segmentation
      • 7.1.3.1 Orthopedics
      • 7.1.3.2 Thyroid
      • 7.1.3.3 Cardiology
      • 7.1.3.4 Others
    • 7.1.4 Market Forecast (2025-2033)
  • 7.2 PET Applications
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Segmentation
      • 7.2.3.1 Oncology
      • 7.2.3.2 Cardiology
      • 7.2.3.3 Neurology
      • 7.2.3.4 Others
    • 7.2.4 Market Forecast (2025-2033)

8 Japan Nuclear Imaging Market - Competitive Landscape

  • 8.1 Overview
  • 8.2 Market Structure
  • 8.3 Market Player Positioning
  • 8.4 Top Winning Strategies
  • 8.5 Competitive Dashboard
  • 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

  • 9.1 Company A
    • 9.1.1 Business Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Business Strategies
    • 9.1.4 SWOT Analysis
    • 9.1.5 Major News and Events
  • 9.2 Company B
    • 9.2.1 Business Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Business Strategies
    • 9.2.4 SWOT Analysis
    • 9.2.5 Major News and Events
  • 9.3 Company C
    • 9.3.1 Business Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Business Strategies
    • 9.3.4 SWOT Analysis
    • 9.3.5 Major News and Events
  • 9.4 Company D
    • 9.4.1 Business Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Business Strategies
    • 9.4.4 SWOT Analysis
    • 9.4.5 Major News and Events
  • 9.5 Company E
    • 9.5.1 Business Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Business Strategies
    • 9.5.4 SWOT Analysis
    • 9.5.5 Major News and Events

10 Japan Nuclear Imaging Market - Industry Analysis

  • 10.1 Drivers, Restraints and Opportunities
    • 10.1.1 Overview
    • 10.1.2 Drivers
    • 10.1.3 Restraints
    • 10.1.4 Opportunities
  • 10.2 Porters Five Forces Analysis
    • 10.2.1 Overview
    • 10.2.2 Bargaining Power of Buyers
    • 10.2.3 Bargaining Power of Suppliers
    • 10.2.4 Degree of Competition
    • 10.2.5 Threat of New Entrants
    • 10.2.6 Threat of Substitutes
  • 10.3 Value Chain Analysis

11 Appendix